Cargando…

Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors

Treatment of non small cell lung cancer (NSCLC) and colorectal cancer (CRC) have substantially changed in the last years with the introduction of epidermal growth factor receptor (EGFR) inhibitors in the clinical practice. The understanding of mechanisms which regulate cells sensitivity to these dru...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morgillo, Floriana, Martinelli, Erika, Troiani, Teresa, Orditura, Michele, De Vita, Ferdinando, Ciardiello, Fortunato
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235154/ https://www.ncbi.nlm.nih.gov/pubmed/22174910 http://dx.doi.org/10.1371/journal.pone.0028841

Ejemplares similares

Critical appraisal of the use of regorafenib in the management of colorectal cancer
por: Festino, Lucia, et al.
Publicado: (2013)

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines
por: Vitiello, Pietro Paolo, et al.
Publicado: (2019)

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells
por: Della Corte, Carminia Maria, et al.
Publicado: (2015)

Correction: Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Corte, Carminia Maria Della, et al.
Publicado: (2022)

Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells
por: Napolitano, Stefania, et al.
Publicado: (2017)

Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
Publicado: (2019)

Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation
por: Napolitano, Stefania, et al.
Publicado: (2017)

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
por: Troiani, Teresa, et al.
Publicado: (2016)

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care
por: Martinelli, Erika, et al.
Publicado: (2007)

Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the COVID-19 Pandemic
por: Napolitano, Stefania, et al.
Publicado: (2022)

Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC
por: Ciaramella, Vincenza, et al.
Publicado: (2019)

Role and targeting of anaplastic lymphoma kinase in cancer
por: Della Corte, Carminia Maria, et al.
Publicado: (2018)

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors
por: Morgillo, F, et al.
Publicado: (2011)

Mechanisms of resistance to EGFR-targeted drugs: lung cancer
por: Morgillo, Floriana, et al.
Publicado: (2016)

Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells
por: Morgillo, Floriana, et al.
Publicado: (2017)

Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells
por: Ciaramella, Vincenza, et al.
Publicado: (2018)

Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
por: Caputo, Vincenza, et al.
Publicado: (2022)

Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models
por: Belli, Valentina, et al.
Publicado: (2019)

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures
por: Della Corte, Carminia Maria, et al.
Publicado: (2019)

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis
por: FEDERICO, ALESSANDRO, et al.
Publicado: (2015)

Role of HGF–MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer
por: Della Corte, Carminia Maria, et al.
Publicado: (2014)

Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass
por: Orditura, Michele, et al.
Publicado: (2007)

Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment
por: Martinelli, Erika, et al.
Publicado: (2017)

Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab
por: Martini, Giulia, et al.
Publicado: (2022)

ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
por: Ryan, A J, et al.
Publicado: (2005)

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression
por: Napolitano, S., et al.
Publicado: (2019)

Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis
por: Orditura, Michele, et al.
Publicado: (2016)

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
por: Franzese, Elisena, et al.
Publicado: (2020)

Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania ‘Luigi Vanvitelli’
por: De Falco, Vincenzo, et al.
Publicado: (2020)

Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population
por: Petrillo, Angelica, et al.
Publicado: (2020)

Towards the era of precision medicine in metastatic colorectal cancer
por: Napolitano, Stefania, et al.
Publicado: (2020)

Present and future of metastatic colorectal cancer treatment: A review of new candidate targets
por: Martini, Giulia, et al.
Publicado: (2017)

Implication of the Hedgehog pathway in hepatocellular carcinoma
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes
por: Diana, Anna, et al.
Publicado: (2020)

AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma
por: Zito Marino, Federica, et al.
Publicado: (2022)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives
por: Ciaramella, Vincenza, et al.
Publicado: (2018)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
por: Ciardiello, Davide, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jq55fjqd0sm70j4c613d6k231l